28,610 Shares in Cogent Biosciences, Inc. $COGT Purchased by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D purchased a new stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 28,610 shares of the technology company’s stock, valued at approximately $1,016,000.

A number of other large investors also recently bought and sold shares of COGT. Osaic Holdings Inc. boosted its position in Cogent Biosciences by 41.4% in the 2nd quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after purchasing an additional 1,333 shares in the last quarter. Strs Ohio purchased a new position in shares of Cogent Biosciences during the 1st quarter valued at approximately $36,000. GAMMA Investing LLC lifted its stake in shares of Cogent Biosciences by 91.7% in the 4th quarter. GAMMA Investing LLC now owns 1,369 shares of the technology company’s stock valued at $49,000 after purchasing an additional 655 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Cogent Biosciences by 35.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the technology company’s stock worth $66,000 after buying an additional 488 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Cogent Biosciences by 22.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,401 shares of the technology company’s stock worth $78,000 after buying an additional 1,003 shares in the last quarter.

Cogent Biosciences Price Performance

Shares of NASDAQ COGT opened at $34.10 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 15.14 and a current ratio of 15.14. The firm has a fifty day moving average of $36.14 and a 200 day moving average of $35.07. The firm has a market cap of $5.83 billion, a PE ratio of -15.71 and a beta of 0.37. Cogent Biosciences, Inc. has a one year low of $4.55 and a one year high of $43.73.

Cogent Biosciences (NASDAQ:COGT) last announced its earnings results on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.53). As a group, research analysts predict that Cogent Biosciences, Inc. will post -2.18 EPS for the current fiscal year.

Analyst Ratings Changes

COGT has been the subject of a number of recent analyst reports. Piper Sandler lifted their price objective on shares of Cogent Biosciences from $39.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Wall Street Zen cut Cogent Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Wedbush restated an “outperform” rating and issued a $55.00 price target on shares of Cogent Biosciences in a research note on Tuesday, March 17th. Jefferies Financial Group initiated coverage on Cogent Biosciences in a report on Monday, March 16th. They issued a “buy” rating and a $55.00 price target for the company. Finally, Robert W. Baird set a $35.00 price target on Cogent Biosciences in a research report on Thursday, February 19th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Cogent Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $43.73.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.